AU699386B2 - A pharmaceutical composition for lowering the blood pressure and a process for the preparation thereof - Google Patents
A pharmaceutical composition for lowering the blood pressure and a process for the preparation thereof Download PDFInfo
- Publication number
- AU699386B2 AU699386B2 AU23269/95A AU2326995A AU699386B2 AU 699386 B2 AU699386 B2 AU 699386B2 AU 23269/95 A AU23269/95 A AU 23269/95A AU 2326995 A AU2326995 A AU 2326995A AU 699386 B2 AU699386 B2 AU 699386B2
- Authority
- AU
- Australia
- Prior art keywords
- mass
- nifedipine
- solution
- ethyl oleate
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 15
- 230000036772 blood pressure Effects 0.000 title claims description 10
- 238000000034 method Methods 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 6
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 45
- 229960001597 nifedipine Drugs 0.000 claims description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- -1 poly(ethylene glycol) Polymers 0.000 claims description 27
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 25
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 25
- 229940093471 ethyl oleate Drugs 0.000 claims description 25
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000001077 hypotensive effect Effects 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 238000004040 coloring Methods 0.000 claims description 3
- 239000012456 homogeneous solution Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 8
- 210000002200 mouth mucosa Anatomy 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical group C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000343203 Lidia Species 0.000 description 1
- 241001601804 Margites Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 229950009941 chloralose Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009474 immediate action Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
1
AUSTRALIA
Patents Act 1990
V~
Ii COMPLETE SPECIFICATION FOR A STANDARD PATENT Name of Applicant: Actual Inventors: Address for Service: EGIS GY6GYSZERGYAR RT.
dr. Margit NAGY n~e Kriscfalussy dr. Csaba FARSANG Lidia FEDINA dr. Katalin SZEMER2DI G~bor SZENASI 36nos EGRI Antal MOSONYI Borb~la BARTA Gizella TOTH n6e Gyarmati Ibolya NYARADI dr. Frigyes GORGENYI Zsuzsa ORR G~za FLORIS CULLEN CO., Patent Trade Mark Attorneys, 240 Queen Street, Brisbane, Qld. 4000, Australia.
A PHARMACEUTICAL COMPOSITION FOR LOWERING THE BLOOD PRESSURE AND A PROCESS FOR THE PREPARATION THEREOF ft ftft I ft ft ''ft.
ft .tft C I I. ft C ft. ft ft ft Invention Title: The following statement is a full description of this invention, including the best method of performing it known to us, 1 a i -la- The invention refers to a pharmaceutical composition and a process for the preparation thereof. Specifically, the invention refers to a sprayable nifedipine solution that comprises 1 to 5 by mass of nifedipine, 5 to 24 by mass of poly(ethylene glycol), 50 to 70 by mass of ethanol, to 30 by mass of propylene glycol and 0.1 to 0.5 by mass of additive(s) and a process for preparing the solution.
It is known that the blood circulation is effectively regulated by 4-(2-nitrophenyl)-2,6-dimethyl-3,5-dimethoxycarbonyl-1,4-dihydropyridine known under the international Snon-proprietory name of nifedipine, thus, it is widely employed S. 15 in various types of pharmaceutical compositions for the treatment of morbid conditions connected with the blood circulation.
The low solubility of nifedipine is a serious problem as to the absorption from solid pharmaceutical compositions as well as maintaining the nifedipine in a dissolved state in case of liquid pharmaceutical compositions. The above difficulties are often solved by adding huge quantities of surface active agents to the pharmaceutical compositions.
Recently, solid pharmaceutical compositions of nifedipine are available that produce either a relatively prolonged action, or a relatively quick action after administration. However, the treatment of anginal attacks or hypertonic emergency conditions requires a simple procedure of administration and, thereafter, an immediate action. In principle, these requirements are sooner met by liquid pharmaceutical compositions, especially the sprayable solutions.
A solution is described in DE-P 33 07 422 that can be administered either perorally in the form of drops, or in intravenous infusion. The known solution contains 0.5 to by mass of a dihydropyridine derivative e.g. nifedipine, 20 to 60 by mass of a solubility enhancing agent, preferably an ester of glyceryl-poly(ethylene glycol) and 80 to 40 by mass of a diluent consisting of water, ethanol, propylene glycol and/or poly(ethylene glycol). The drawback of the known composition resides in the rather high content of surface active agent that can lead to irritations of the oral mucosa in case .of peroral administration.
f 9 A sprayable solution is known from DE-P 35 44 692 wherein the dihydropyridine derivative such as nifedipine is dissolved in poly(ethylene glycol) and ethanol, optionally in the presence 15 of water and glycerol, and the solution contains 3 to 15 by mass of polyvinylpyrrolidone. According to the description, the active agent of the pharmaceutical composition has a quick action, however, it is a disadvantage of the known composition 9 *t that the polyvinylpyrrolidone easily forms a solid film, thus, 20 the spraying nozzle is often clogged due to drying of the polyvinylpyrrolidone. Even if the nozzle is not completely clogged, the amount of the sprayed nifedipine dosage becomes uncertain in the presence of polyvinylpyrrolidone since the sprayed dosage is lower than the required quantity until the solid polyvinylpyrrolidone separated in the nozzle is washed out by the solvent. Thus, if the known pharmaceutical composition is rarely used, the sprayed dosage will be always lower than the prescribed amount.
From EP 190 292 a pharmaceutical composition is known that can be transformed to an aerosol. The composition consists of -3nifedipine dissolved in a solvent containing poly(ethylene glycol) and/or glyceryl-poly(ethylene glycol)-oxystearate, and the solution is atomized by means of a propellant or a pump in a carrier gas stream. According to the examples of the description, the solvent consists of ethanol that may contain water and glycerol, too. A composition suitable for sublingual administration is also shown by certain examples.
In accordance with our examinations, the hypotensive action of the known pharmaceutical composition is not sufficient for the effective treatment of anginal attacks or hypertonic o. emergency conditions.
The aim of the invention is to provide a solution that S" can be sprayed by means of a pump, being suitable for sublingual administration and even a low dosage of it lowers the blood pressure in a short time.
S It was found that the above aim is fulfilled by a nifedipine solution containing, in addition to the conventional ingredients of nifedipine solutions, 2 to 4 by mass of ethyl oleate.
i n 4.
Ic is surprising tnat the nypotensive action oi nareaipin becomes significantly higher in the presence of 2 to 4 by mass of ethyl oleate, i.e. synergism is experienced between nifedipine and 2 to 4 by mass of ethyl oleate (the percentage of ethyl oleate refers to the mass of the whole composition).
The above synergism was shown by the following test: In the examinations, LATI and Charles River male rats were used that were hypertonic in a spontaneous manner. For each dose, 8 animals weighing 250 to 300 g each were employed. The animals were an(esthesized by the ip. administration of 90 mg/kg of chloralose and 600 mg/kg of urethane, then they were tracheotomized and a catheter was introduced into the left r
I
-4femoral artery of each rat. The blood pressure was determined and continuously recorded by a tonometer type Statham P 23Gb.
minutes after the surgical intervention a 10 minutes control period was left, then the sample to be examined was transferred to the oral mucosa of the animals, and the blood pressure was recorded for further 60 minutes.
The samples to be examined were as follows: Solution of Example 1. The dose transferred to the oral mucosa cnntained 3 mg of nifedipine and 3 by mass of ethyl oleate !the latter figure referring to the mass of the solution administered).
A solution similar to that of Example 1, however,.
comprising 2.5 by mass of ethyl oleate. The dose I transferred to the oral mucosa contained 3 mg of
S
I 15 nifedipine and 2.5 by mass of ethyl oleate (the latter figure referring to the mass of the solution a.
administered).
A solution similar to that of Example 1, however, comprising 3.5 by mass of ethyl oleate. The dose transferred to the oral mucosa contained 3 mg of nifedipine and 3.5 by mass of ethyl oleate (the latter figure referring to the mass of the solution administered).
A solution similar to that of Example 1, however, without any ethyl oleate. The dose transferred to the oral mucosa contained 3 mg of nifedipine.
A solution similar to that of Example 1, however, without any nifedipine. The dose transferred to the oral mucosa contained 3 by mass of ethyl oleate (the latter figure referring to the mass of the solution).
:13 D In case of deviation from the composition of Example 1, the amount of the solvents was increased or decreased according to the change of the quantity of ethyl oleate and the omission of nifedipine, respectively. In each case an amount of solution comprising 3 mg of nifedipine was administered to the animals.
(The same amount 0.103 g of the solution without any nifedipine was administered, too.) The reduction of blood pressure produced by the solutions examined are shown in the following Table. The blood pressures determined 10, 20, 30, 40, 50 and 60 minutes after the administration of the solution examined were compared to the blood pressure value determined before the administration of the solution to obtain the reductions given in the Table.
94*9 9 99 94 9 9 *4 *1 99 9 9) 44 *r 9 99r 9 9'4* 9.
99 9 .4.
Table Sample examined Reduction of blood pressure in mm Hg 10 20 30 40 50 minutes after the treatment 3 mg of nifedipine -27 3% of ethyl oleate 4 3 mg of nifedipine of ethyl oleate -38 3 mg of nifedipine 3% of ethyl oleate -44 3 mg of nifedipine of ethyl oleate -40 -29 5 -31 -30 -29 -28 4 4 4 3 -43 -42 -40 -41 -39 -44 -46 -47 -45 -42 -47 -49 -48 -47 1 -6- 0400 0 *1 00 0 S4 *i 4 00 0 00* 0 0* From the above data it can be seen that the hypotensive action of the composition of the invention is significantly higher than the sum of the hypotensive effect of the constituents when determined separately. Thus, there is a synergism between nifedipine and ethyl oleate.
The sprayable nifedipine solution of the invention is prepared by forming a solution from 1 to 5 by mass of nifedipine, 5 to 24 by mass of poly(ethylene glycol), 50 to by mass of ethanol, 10 to 30 by mass of propylene glycol and 0.1 to 0.5 by mass of additive(s) in a manner known per se, and admixing 2 to 4 by mass of ethyl oleate to the nifedipine solution during the preparation thereof.
In general, nifedipine is dissolved in a mixture of the organic solvents or a part thereof, and the remaining ingredients are added to the nifedipine solution obtained. The ethyl oleate is admixed to the organic solvent mixture comprising nifedipine, either before or after the addition of the remaining ingredients.
The one or more additive(s) can be a flavouring agent, a colouring agent etc.
The solution obtained is preferably filtered and filled into aerosol containers. A suitable pump is placed into each container, the latter is sealed and equipped with a spraying nozzle. Since nifedipine is rather sensitive to light, during the above operations the nifedipine solution should be protected from light.
The pharmaceutical composition of the invention is well absorbed sublingually and has a considerable effect in a very short time, thus, it is suitable for the effective treatment of anginal attacks or hypertonic emergency conditions. Spraying 0 is performed in a mechanical way by means of a pump, -I consequently, the environment is not loaded by any propellant.
The invention is further elucidated by means of the following Examples.
Example 1 2.9 parts by mass of nifedipine are added to a mixture of 10 parts by mass of poly(ethylene glycol) (molecular weight: 400) and 18.2 parts by mass of propylene glycol. The mixture obtained is heated to 75 °C under stirring, then 3 parts by mass of ethyl oleate and 65.8 parts by mass of ethyl alcohol are added, and stirring is continued at 75 The homogeneous solution is cooled to 35-40 0.1 parts by mass of a flavouring agent are added, stirred for further 5 minutes, then filtered through a glass filter having a pore size of G4 under nitrogen The filtrate is filled into aerosol containers of 20 g capacity, 9 S 15 a mechanical sprayer pump) is placed into each container that is sealed and equipped with a spraying nozzle.
Example 2 parts by mass of nifedipine are dissolved in a mixture of 10 parts by mass of poly(ethylene glycol) (molecular weight: 9 20 400) and 64.5 parts by mass of ethyl alcohol at 55-60 °C under stirring. To the solution obtained 16.9 parts by mass of propylene glycol and 3.5 parts by mass of ethyl oleate are admixed, the mixture is cooled to 35 C and 0.1 parts by mass of a flavouring agent are added under stirring, Then the procedure of Example 1 is followed.
Example 3 1 parts by mass of nifedipine is dissolved in 65.4 parts by mass of ethyl alcohol at 55-60 °C under stirring, then 12 parts by mass of poly(ethylene glycol) and 19 parts by mass -"of propylene glycol are added under constant stirring at the, sam-1 temperature. To the solution obtained 2.5 parts by mass of ethyl oleate are admixed, the mixture is cooled to 350 and 0.1 parts by mass of a flavouring agent are added. Then.
the procedure of Example 1 is followed.
*too
Claims (2)
1. A sprayable solution that comprises 1 to 5% by mass of nifedipine, 5 to 24% by mass of poly(ethylene glycol), 50 to 70% by mass of ethanol, 10 to 30% by mass of propylene glycol and 0.1 to 0.5% by mass of flavouring and/or colouring agent, characterised by also containing 2 to 4% by mass of ethyl oleate to enhance the hypotensive effect of nifedipine.
2. A process for preparing a sprayable nifedipine solution by forming a homogeneous solution comprising from 1 to 5% by mass of nifedipine, 5 to 24% by mass of poly(ethylene glycol), 50 to 70% by mass of o ethanol, 10 to 30% by mass of propylene glycol and 0.1 to 0.5% by mass of flavouring and/or colouring agent, characterized by admixing 2 to 4% by mass of ethyl oleate to the nifedipine solution during the preparation thereof. a DATED this 2 9 th day of September 1998 EGIS GY6GYSZERGYAR RT. By their Patent Attorneys CULLEN CO. *a S r- a /i^a Abstract A pharmaceutical composition for lowering the blood pressure and a process for the preparation thereof The invention refers to a sprayable nifedipine solution that comprises 1 to 5 by mass of nifedipine, 5 to 24 by m&as of poly(ethylene glycol), 50 to 70 by mass of ethanol, to 30 by mass of propylene glycol and 0.1 to 0.5 by mass S. of additive(s), said solution containing, in addition to.the above conventional ingredients of nifedipine solutions, 2 to 4 by mass of ethyl oleate. l* e 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP9402193 | 1994-07-26 | ||
| HU9402193A HU214582B (en) | 1994-07-26 | 1994-07-26 | Spayable antihypertensive composition and process for it`s production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2326995A AU2326995A (en) | 1996-02-08 |
| AU699386B2 true AU699386B2 (en) | 1998-12-03 |
Family
ID=10985460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU23269/95A Ceased AU699386B2 (en) | 1994-07-26 | 1995-06-27 | A pharmaceutical composition for lowering the blood pressure and a process for the preparation thereof |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPH08169829A (en) |
| AT (1) | AT402690B (en) |
| AU (1) | AU699386B2 (en) |
| BE (1) | BE1011413A4 (en) |
| CZ (1) | CZ286399B6 (en) |
| DE (1) | DE19527140A1 (en) |
| EE (1) | EE9500029A (en) |
| FR (1) | FR2722988B1 (en) |
| GB (1) | GB2291593B (en) |
| HR (1) | HRP950374A2 (en) |
| HU (1) | HU214582B (en) |
| IT (1) | IT1277348B1 (en) |
| LT (1) | LT4042B (en) |
| LV (1) | LV11026B (en) |
| PL (1) | PL181069B1 (en) |
| SK (1) | SK280463B6 (en) |
| UA (1) | UA39880C2 (en) |
| YU (1) | YU50795A (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7632517B2 (en) | 1997-10-01 | 2009-12-15 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
| US20030095925A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
| AU4894697A (en) * | 1997-10-01 | 1999-04-23 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
| EP1848270B1 (en) * | 2005-02-17 | 2014-05-21 | Abbott Laboratories | Transmucosal administration of drug compositions for treating and preventing disorders in animals |
| DE102006027794A1 (en) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Antihypertensive combination wafer |
| FR2906140B1 (en) * | 2006-09-22 | 2008-12-05 | Philippe Perovitch | GALENIC FORM FOR TRANSMUCOSUS ADMINISTRATION OF ACTIVE INGREDIENTS |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| US5298258A (en) * | 1989-12-28 | 1994-03-29 | Nitto Denko Corporation | Acrylic oily gel bioadhesive material and acrylic oily gel preparation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3307422A1 (en) * | 1983-03-03 | 1984-09-06 | Bayer Ag, 5090 Leverkusen | LIQUID PREPARATIONS OF DIHYDROPYRIDINES, A METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN THE FIGHT AGAINST DISEASES |
| EP0175671A1 (en) | 1984-08-23 | 1986-03-26 | Kuhlemann & Co. | Pharmaceutical preparation and method for the administration of this pharmaceutical preparation |
| DE3544692A1 (en) * | 1985-12-18 | 1987-06-19 | Bayer Ag | DIHYDROPYRIDINE SPRAY, METHOD FOR THE PRODUCTION THEREOF AND ITS PHARMACEUTICAL USE |
| US4869899A (en) * | 1986-03-10 | 1989-09-26 | Walter Burghart | Pharmaceutical preparation and process for producing the same |
| EP0267617B1 (en) * | 1986-11-14 | 1992-06-24 | Theratech, Inc. | Penetration enhancement with binary system of cell envelope disordering compounds and lower alcohols |
| JPS63170316A (en) * | 1986-12-30 | 1988-07-14 | Fujimoto Seiyaku Kk | Percutaneously absorbable pharmaceutical of nifedipine for external use |
| DE3714402A1 (en) * | 1987-04-30 | 1988-11-10 | Kali Chemie Pharma Gmbh | DRUG FORMULATION |
| GB8828477D0 (en) * | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| AT391269B (en) * | 1988-12-30 | 1990-09-10 | Burghart Kurt | PHARMACEUTICAL PREPARATION |
| HU205249B (en) * | 1990-11-09 | 1992-04-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing suspensive aerosole composition |
-
1994
- 1994-07-26 HU HU9402193A patent/HU214582B/en unknown
-
1995
- 1995-06-27 AU AU23269/95A patent/AU699386B2/en not_active Ceased
- 1995-06-30 HR HRP9402193A patent/HRP950374A2/en not_active Application Discontinuation
- 1995-07-13 CZ CZ19951811A patent/CZ286399B6/en not_active IP Right Cessation
- 1995-07-17 FR FR9508598A patent/FR2722988B1/en not_active Expired - Fee Related
- 1995-07-17 AT AT0121495A patent/AT402690B/en not_active IP Right Cessation
- 1995-07-20 LT LT95-084A patent/LT4042B/en not_active IP Right Cessation
- 1995-07-20 SK SK922-95A patent/SK280463B6/en unknown
- 1995-07-21 JP JP7185275A patent/JPH08169829A/en active Pending
- 1995-07-24 BE BE9500646A patent/BE1011413A4/en not_active IP Right Cessation
- 1995-07-24 PL PL95309757A patent/PL181069B1/en not_active IP Right Cessation
- 1995-07-25 EE EE9500029A patent/EE9500029A/en unknown
- 1995-07-25 GB GB9515205A patent/GB2291593B/en not_active Expired - Fee Related
- 1995-07-25 UA UA95073513A patent/UA39880C2/en unknown
- 1995-07-25 DE DE19527140A patent/DE19527140A1/en not_active Withdrawn
- 1995-07-25 LV LVP-95-225A patent/LV11026B/en unknown
- 1995-07-26 IT IT95MI001621A patent/IT1277348B1/en active IP Right Grant
- 1995-07-26 YU YU50795A patent/YU50795A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| US5298258A (en) * | 1989-12-28 | 1994-03-29 | Nitto Denko Corporation | Acrylic oily gel bioadhesive material and acrylic oily gel preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9515205D0 (en) | 1995-09-20 |
| LV11026A (en) | 1996-02-20 |
| LT4042B (en) | 1996-09-25 |
| HUT75457A (en) | 1997-05-28 |
| ITMI951621A1 (en) | 1997-01-26 |
| FR2722988B1 (en) | 1999-10-08 |
| CZ181195A3 (en) | 1996-02-14 |
| PL309757A1 (en) | 1996-02-05 |
| HU214582B (en) | 1998-04-28 |
| YU50795A (en) | 1998-05-15 |
| EE9500029A (en) | 1996-02-15 |
| JPH08169829A (en) | 1996-07-02 |
| IT1277348B1 (en) | 1997-11-10 |
| CZ286399B6 (en) | 2000-04-12 |
| LT95084A (en) | 1996-06-25 |
| UA39880C2 (en) | 2001-07-16 |
| PL181069B1 (en) | 2001-05-31 |
| FR2722988A1 (en) | 1996-02-02 |
| GB2291593A (en) | 1996-01-31 |
| HU9402193D0 (en) | 1994-09-28 |
| HRP950374A2 (en) | 1997-10-31 |
| ITMI951621A0 (en) | 1995-07-26 |
| ATA121495A (en) | 1996-12-15 |
| AU2326995A (en) | 1996-02-08 |
| AT402690B (en) | 1997-07-25 |
| LV11026B (en) | 1996-04-20 |
| GB2291593B (en) | 1998-03-11 |
| DE19527140A1 (en) | 1996-02-01 |
| SK92295A3 (en) | 1996-05-08 |
| BE1011413A4 (en) | 1999-09-07 |
| SK280463B6 (en) | 2000-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5047230A (en) | Aerosol composition comprising nitroglycerin as active ingredient | |
| US4734284A (en) | Etoposide preparations | |
| AU602931B2 (en) | Coating membrane and compositions prepared therefrom | |
| JP2793906B2 (en) | Novel therapeutically active compounds and their preparation | |
| WO2000059475A1 (en) | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents | |
| US4138565A (en) | Stable solutions and processes for their preparation | |
| AU699386B2 (en) | A pharmaceutical composition for lowering the blood pressure and a process for the preparation thereof | |
| CH645805A5 (en) | SUPPOSITORIES CONTAINING A LINK WITH BRONCHODILATION ACTIVITY. | |
| AU765560B2 (en) | New process for the purification of aldehyde impurities | |
| EP1137653B1 (en) | Troxerutin with high trihydroxy-ethyl-rutin content and method for preparing same | |
| FR2609394A1 (en) | AQUEOUS SOLUTION CONTAINING QUINOLONE CARBOXYLIC ACID | |
| US4402949A (en) | Stable solutions of hydrogenated ergotalkaloids | |
| AU707220B2 (en) | Pharmaceutical composition for parenteral application containing an indole-carboxylic acid | |
| DE69807745T2 (en) | MONOARGININYL SALT OF (E) -3- [1-N-BUTYL-5 - [(2- (2-CARBOXYPHENYL) METHOXY-4-CHLORPHENYL] -1H-PYRAZOL-4-YL] -2 - [(5-METHOXY- 2,3-DIHYDROBENZOFURAN-6-YL) METHYL] -PROP-2-EN CARBONIC ACID | |
| IE47791B1 (en) | Stable solutions of hydrogenated ergopeptide alkaloids | |
| BE1006829A3 (en) | Pharmaceutical solid. | |
| HU179989B (en) | Process for preparing pharmacological compositions containing r-/+/-1-/1-phenyl-ethyl/-1h-imidazol-5-carboxylic acid ethyl ester for intravenous administration | |
| JPH01153686A (en) | Azelastine enbonate, its production, preparation containing said compound, stable aqueous suspension and aerosol, production thereof and production of suspension and solid preparation | |
| JPH0283323A (en) | Stable riboflavin butyrate aqueous solution | |
| EP0326103A1 (en) | Pharmaceutical composition for 4-aroylimidazol-2-ones | |
| FR2537435A1 (en) | NEW DRUG ASSOCIATION BASED ON A HYDROGEN ALKALOID OF ERGOT AND HEPARIN | |
| JPH0830010B2 (en) | Picosulfate sodium liquid filled hard capsule | |
| FI72651B (en) | FOERFARANDE FOER FRAMSTAELLNING AV EN LAONGTIDSVERKANDE INJEKTIONSLOESNING AV SULFAMETAZIN. | |
| HU188202B (en) | Process for production of stabilized, injectable medical preparates consisting of - as reagents - 2-(4-)3-/2- chlorine-phentiazine-10-il/-propil)-1-piperazinil/-ethil /3,4,5-trimetoxi/benzoate-diethansulphonate | |
| JPS57106679A (en) | Novel piperidne derivative, its preparation, and pharmaceutical composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |